Affiliation:
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine Iwate Medical University, School of Medicine Shiwa‐gun Japan
2. Department of Urology Iwate Medical University, School of Medicine Shiwa‐gun Japan
Abstract
AbstractIntroductionThe aim is to clarify the hepatitis C virus (HCV) status of hemodialysis (HD) patients and patient management after HCV elimination.MethodsQuestionnaire survey was conducted in Iwate prefecture, Japan from 2016 to 2021.ResultsPatients underwent HD was 2944, including 132 anti‐HCV antibody‐positive patients, with 91 HCV RNA‐positive patients. Of the 91 HCV RNA‐positive patients, 51 received antiviral treatment. Sustained virological response (SVR) rate was 94%. The patients treated with direct antiviral agents had significantly lower mortality rate than the untreated patients, and no liver‐related deaths occurred in patients who achieved SVR or in HCV RNA‐negative patients. The HCV RNA‐positive prevalence was finally 0.79%. Approximately 40% of the facilities had dedicated beds and dialysis‐related items for patients who achieved an SVR.ConclusionTo eliminate HCV in HD facilities, it is necessary to promote HCV RNA testing for anti‐HCV antibody‐positive patients and to provide antiviral treatment for HCV RNA‐positive patients. Additionally, collaboration among hepatologists and HD specialists are essential.